Navidea Biopharmaceuticals Inc IPO-Jahr
Was ist das IPO-Jahr von Navidea Biopharmaceuticals Inc?
IPO-Jahr von Navidea Biopharmaceuticals Inc ist 1992
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf NYSEMKT im Vergleich zu Navidea Biopharmaceuticals Inc
Was macht Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Unternehmen mit ipo-jahr ähnlich Navidea Biopharmaceuticals Inc
- International Paper APPM hat IPO-Jahr von 1991
- HomeServe Plc hat IPO-Jahr von 1991
- PS Business Parks hat IPO-Jahr von 1991
- Nuveen Michigan Quality Municipal Income Fund hat IPO-Jahr von 1991
- Nuveen Ohio Quality Municipal Income Fund hat IPO-Jahr von 1991
- Tivity Health Inc hat IPO-Jahr von 1991
- Navidea Biopharmaceuticals Inc hat IPO-Jahr von 1992
- ParkerVision hat IPO-Jahr von 1993
- Host Hotels & Resorts Inc hat IPO-Jahr von 1993
- Barrett Business Services hat IPO-Jahr von 1993
- Rocky Brands, Inc hat IPO-Jahr von 1993
- Titan International hat IPO-Jahr von 1993
- Regency Centers hat IPO-Jahr von 1993